# Study of Feasibility and Safety of MDMA-Assisted Group Therapy for the Treatment of PTSD in Veterans

> **NCT05173831** · PHASE2 · WITHDRAWN · sponsor: **Resilient Pharmaceuticals**

## Conditions studied

- PTSD

## Interventions

- **DRUG:** Midomafetamine
- **BEHAVIORAL:** Therapy

## Key facts

- **NCT ID:** NCT05173831
- **Lead sponsor:** Resilient Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2023-09
- **Primary completion:** 2024-12
- **Final completion:** 2024-12
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Transfer of Sponsorship
- **Last updated:** 2024-10-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05173831

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05173831, "Study of Feasibility and Safety of MDMA-Assisted Group Therapy for the Treatment of PTSD in Veterans". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05173831. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*